طبيبة مقيمة في الدنمارك. Views are my own . Clinical Oncologist Denmark
Joined July 2008
- Tweets14.2K
- Following878
- Followers1.7K
- Likes3.8K
azza khalil retweeted
Presented at #ESMO25:
In EGFR-mutated advanced non–small-cell lung cancer with progression after EGFR-TKI therapy, sacituzumab tirumotecan led to better progression-free and overall survival outcomes than chemotherapy. Full OptiTROP-Lung04 phase 3 trial results: nej.md/493hVjl
@myESMO
ALT European Society for Medical Oncology Original Article | October 19, 2025 | NEJM.org Sacituzumab Tirumotecan in EGFR-TKI– Resistant, EGFR-Mutated Advanced NSCLC Figure 1A. Progression-free Survival. NEJM identity sits at the bottom.
azza khalil retweeted
📢 #ESMO25 concomitant paper: results from the largest and most diverse international, multicenter, retrospective study on leptomeningeal metastases from #NSCLC @Nicmmzh126
bit.ly/3J5dlqk
azza khalil retweeted
📢 #ESMO25 concomitant paper: results from the largest and most diverse international, multicenter, retrospective study on leptomeningeal metastases from #NSCLC @Nicmmzh126
bit.ly/3J5dlqk
Really meaningful work
#ESMO25
Thank you to the scientific committee for selecting our work for oral presentation:
Patient-level analysis of Pneumonitis in Nivo-based regimens for solid tumors:
- 11,777pts, 716 with pneumonitis (6.1%)
- risk factors: age >65; NSCLC, smoking+, Ipi/nivo (p<0.005)
1/3
azza khalil retweeted
Israeli orchestral conductor Ilan Volkov gave a heartfelt speech urging the world to stop Israel's slaughter in Gaza and help free the hostages in Gaza and in Israel.
azza khalil retweeted
EGFR update
7 potential options:
•3rd gen TKI: osimertinib, lazertinib, aumolertinib
•Amivantamab
•Pemetrexed
•Carboplatin
•Ivonescimab
•Dato-DXd
OS data favor combos upfront—but real-world ≠ trial. In RWD, ~40% of newly diagnosed pts wouldn’t qualify for FLAURA2 #WCLC25
azza khalil retweeted
#WCLC25 Presidential
FLAURA2 OS in 1L EGFR+ NSCLC:
- mOS 47.5m v 37.6m (HR 0.77 p=0.02)
- duration of osi 30.5m on osi+chemo v 21.2m osi- combo delays acq resistance? - 72% got 2L chemo- does this add ~9m?
- all subgrps benefit (?BM, ?co-mtns)
Congrats @dplanchard @iaslc #LCSM
azza khalil retweeted
Funny how two of the more interesting pieces of data at #ASCO25 have little to do with extraneous medications per se, but rather the body’s circadian rhythm and physiology:
1: Exercise after surgery
2: Checkpoint inhibitors in the morning
azza khalil retweeted
Being part of a history-making drug that helps pts with #SCLC live longer and better is the biggest reward a thoracic oncologist could hope for.
Grateful being involved and to our pts
Just out in @NEJM
Presentation today by 1@only @charlesrudin
#ASCO25
azza khalil retweeted
The most practice changing trial from #ASCO25 is now live on @NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival.
Perfect case example of a #cancergroundshot trial.
nejm.org/doi/full/10.1056/NE…
azza khalil retweeted
Putting Pacific into real world conditions, another important piece of information. Thank you for the invitation!
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer—final analysis from the phase II PACIFIC-6 trial in @ESMO_Open.mOS and mPFS 39 and 13.1 months, respectively. 6% G3/4 AEs potentially related to tx. esmoopen.com/article/S2059-7…
azza khalil retweeted
#ELCC25 Lung Orals
1L MARIPOSA trial: Ami-Laz v Osi in EGFR+ NSCLC:
- OS benefit, 9% absolute benefit in 3-yr OS (HR 0.74, p<0.05)
- significant tox burden (IRRs, derm tox, VTE), mainly in first 4m, requiring prophylaxis
Throwing the field, on its head @myESMO @OncoAlert #LCSM
azza khalil retweeted
The most awaited slide of the #ELCC25
OS from the MARIPOSA trial. Clearly positive trial reinforcing the interest of Amivantamab + Lazertinib in 1L for EGFR
At what cost 🤔 ? dermatologic tox, VTEs, infusion reaction… High-maintenance treatment ! @OncoAlert
azza khalil retweeted
📣Updated: ESMO Guidelines Slideset: Oncogene-Addicted Metastatic Non-small Cell Lung Cancer v1.2
👉 Find Clinical Practice Guideline recommendations in a condensed format, to include in your presentations.
#ESMOGuidelines
🔗ow.ly/sGmE50VnVwU
azza khalil retweeted
A third girl was just rescued from under the rubble in the suburbs of Beirut, Lebanon❤️🤲🏻
azza khalil retweeted
ازاي كائن حي يخرج من الدمار ده
ليس هناك من استهداف أو محاولة اغتيال ، إنّه تبرير لاستهداف المدنيين …. الضاحية بالقلب ♥️
#الضاحية_بترفع_الراس ✌️♥️♥️♥️✌️
الله يرحم الشهدا ✌️💔✌️
